[Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders].
D V Kurkin, E I Morkovin, D A Bakulin, Yu V Gorbunova, O V Ivanova, E V Pavlova, V I Zvereva, M A Dzhavakhyan, I S Krysanov, Yu A Kolosov, A V Zaborovsky, A V Strygin, V I Petrov, P A Beliy, K Y Zaslavskaya, D V Maltsev, M O Skripka
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2024 DOI: 10.17116/jnevro202412405122 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Ketamine Serotonin |
| Keywords | Ampa Nmda #neuroscience #depression-treatment depression Clinical depression #neurotransmitters glutamate Brain chemicals #psychopharmacology |
| Key findings | Targeting glutamatergic pathways, particularly through modulation of NMDA and AMPA receptors, shows promise for enhancing the efficacy of pharmacotherapy for depressive disorders. |
Abstract
Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in the CNS, particularly through modulation of NMDA and AMPA receptors, demonstrates promising results. This review presents some existing drugs with glutamatergic activity and novel developments based on it to enhance the efficacy of pharmacotherapy for depressive disorders.
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |
Citations in the library
Cites 19
- Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics TIPS - Trends in Pharmacological Sciences September 24, 2021
- Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments The International Journal of Neuropsychopharmacology November 14, 2018
- Long-term safety of ketamine and esketamine in treatment of depression Expert Opinion on Drug Safety April 13, 2022
- Novel drug developmental strategies for treatment‐resistant depression British Journal of Pharmacology November 25, 2021
- Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database of Systematic Reviews September 12, 2021
and 14 more in the library